0

GSK-3β Inhibitor TDZD-8 Reduces Neonatal Hypoxic-Ischemic Brain Injury in Mice

Sammen Huang, Haitao Wang, Ekaterina Turlova, Ahmed Abussaud, Xiang Ji, Luiz R Britto, Steven P Miller, Ana Martinez, Hong-Shuo Sun, Zhong-Ping Feng

CNS Neurosci Ther. 2017 May;23(5):405-415.

PMID: 28256059

Abstract:

Aims:
Glycogen synthase kinase 3β (GSK-3β) is activated following hypoxic-ischemic (HI) brain injury. TDZD-8 is a specific GSK-3β inhibitor. Currently, the impact of inhibiting GSK-3β in neonatal HI injury is unknown. We aimed to investigate the effect of TDZD-8 following neonatal HI brain injury.
Methods:
Unilateral common carotid artery ligation followed by hypoxia was used to induce HI injury in postnatal day 7 mouse pups pretreated with TDZD-8 or vehicle. The infarct volume, whole-brain imaging, Nissl staining, and behavioral tests were used to evaluate the protective effect of TDZD-8 on the neonatal brain and assess functional recovery after injury. Western blot was used to evaluate protein levels of phosphorylated protein kinase B (Akt), GSK-3β, and cleaved caspase-3. Protein levels of cleaved caspase-3, neuronal marker, and glial fibrillary acidic protein were detected through immunohistochemistry.
Results:
Pretreatment with TDZD-8 significantly reduced brain damage and improved neurobehavioral outcomes following HI injury. TDZD-8 reversed the reduction of phosphorylated Akt and GSK-3β, and the activation of caspase-3 induced by hypoxia-ischemia. In addition, TDZD-8 suppressed apoptotic cell death and reduced reactive astrogliosis.
Conclusion:
TDZD-8 has the therapeutic potential for hypoxic-ischemic brain injury in neonates. The neuroprotective effect of TDZD-8 appears to be mediated through its antiapoptotic activity and by reducing astrogliosis.

Chemicals Related in the Paper:

Catalog Number Product Name Structure CAS Number Price
AP327036895-B TDZD-8 TDZD-8 327036-89-5 Price
qrcode